Sight Sciences (SGHT) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - Sight Sciences, Inc. reported revenue of $20.39 million for the quarter ended December 2025, reflecting a year-over-year increase of 6.9% and a surprise of +0.34% over the Zacks Consensus Estimate of $20.32 million [1] - The company's EPS was -$0.08, an improvement from -$0.23 in the same quarter last year, with a surprise of +44.83% compared to the consensus estimate of -$0.15 [1] Revenue Performance - Revenue from Interventional Dry Eye was $0.72 million, exceeding the average estimate of $0.6 million by four analysts, representing a significant year-over-year increase of +138.2% [4] - Revenue from Interventional Glaucoma was reported at $19.66 million, slightly below the average estimate of $19.7 million, with a year-over-year increase of +4.8% [4] Profit Metrics - Gross Profit from Interventional Dry Eye was $0.5 million, surpassing the estimated $0.3 million by three analysts [4] - Gross Profit from Interventional Glaucoma was $17.29 million, exceeding the average estimate of $16.89 million by three analysts [4] Stock Performance - Over the past month, shares of Sight Sciences have returned -18.7%, compared to a -1.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]